We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-6.76%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.35B
AUM Growth
-$253M
Cap. Flow
-$52M
Cap. Flow %
-2.22%
Top 10 Hldgs %
44.73%
Holding
154
New
14
Increased
27
Reduced
18
Closed
11

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.7M
3
JNJ icon
Johnson & Johnson
JNJ
+$12.2M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$11M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.1M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$27.4M
2
A icon
Agilent Technologies
A
+$21.7M
3
CPHD
Cepheid Inc
CPHD
+$17.6M
4
LLY icon
Eli Lilly
LLY
+$16.4M
5
UNH icon
UnitedHealth
UNH
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 90.58%
2 Real Estate 3.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
51
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$10.6M 0.45%
+179,000
New +$11M
ZBH icon
52
Zimmer Biomet
ZBH
$18.4B
$10.6M 0.45%
105,369
– –
BDX icon
53
Becton Dickinson
BDX
$45.6B
$10.4M 0.44%
64,655
– –
NTRA icon
54
Natera
NTRA
$38.6B
$10.3M 0.44%
882,358
– –
FOMX
55
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$10.3M 0.44%
930,398
-35,667
-4% -$336K
MRUS
56
DELISTED
Merus
MRUS
$10.1M 0.43%
479,150
+219,150
+84% +$3.74M
DOC
57
DELISTED
PHYSICIANS REALTY TRUST
DOC
$10.1M 0.43%
530,672
– –
CRL icon
58
Charles River Laboratories
CRL
$11.3B
$9.72M 0.41%
127,600
+12,600
+11% +$957K
ALNY icon
59
Alnylam Pharmaceuticals
ALNY
$27.5B
$9.13M 0.39%
243,995
– –
ARDX icon
60
Ardelyx
ARDX
$1.25B
$9.08M 0.39%
639,370
-68,266
-10% -$969K
CCP
61
DELISTED
Care Capital Properties, Inc.
CCP
$8.63M 0.37%
+345,022
New +$8.66M
CTMX icon
62
CytomX Therapeutics
CTMX
$714M
$8.31M 0.35%
756,090
– –
EXEL icon
63
Exelixis
EXEL
$14.1B
$8.22M 0.35%
551,647
– –
PBYI icon
64
Puma Biotechnology
PBYI
$402M
$7.99M 0.34%
260,200
– –
LKFT
65
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$7.43M 0.32%
115,738
-32,000
-22% -$1.97M
AKRX
66
DELISTED
Akorn Inc
AKRX
$7.15M 0.3%
327,735
+182,500
+126% +$4.2M
AVDL
67
DELISTED
Avadel Pharmaceuticals
AVDL
$6.49M 0.28%
624,288
– –
LTC
68
LTC Properties
LTC
$2.06B
$6.4M 0.27%
136,212
+30,000
+28% +$1.42M
RARE icon
69
Ultragenyx Pharmaceutical
RARE
$2.56B
$6.21M 0.26%
88,400
– –
PVLA
70
Palvella Therapeutics
PVLA
$2.15B
$5.8M 0.25%
51,824
– –
PRAH
71
DELISTED
PRA Health Sciences, Inc.
PRAH
$5.62M 0.24%
102,000
– –
SNR
72
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$5.56M 0.24%
567,997
+137,000
+32% +$1.38M
GBT
73
DELISTED
Global Blood Therapeutics, Inc.
GBT
$5.51M 0.23%
381,300
+256,300
+205% +$4.5M
ICLR icon
74
Icon
ICLR
$12.8B
$5.41M 0.23%
72,000
– –
XENE icon
75
Xenon Pharmaceuticals
XENE
$6.2B
$5.39M 0.23%
700,000
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Tekla Capital Management held 154 positions worth $2.35B, down 9.7% from $2.6B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Tekla Capital Management's Q4 2016 filing shows 14 new, 27 increased, 18 reduced and 11 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 179,000 shares worth $10.6M. The largest sale was Alkermes, an estimated $27.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2016 buy was State Street SPDR S&P Biotech ETF: 179,000 shares worth $10.6M.
  • Tekla Capital Management added most to Biogen in Q4 2016, an estimated $16.4M increase.
  • Tekla Capital Management's biggest Q4 2016 reduction was Eli Lilly, cutting an estimated $16.4M.
  • Tekla Capital Management fully exited Alkermes in Q4 2016, selling an estimated $27.4M.
  • Tekla Capital Management's ten largest holdings make up 45% of its $2.35B portfolio in Q4 2016.
  • Tekla Capital Management opened 14 new positions and closed 11 in Q4 2016.
  • Tekla Capital Management's portfolio value fell 9.7% quarter-over-quarter to $2.35B.

Based on Tekla Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.